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Summary
Background The eradication of wild and vaccine-derived poliovirus requires the global withdrawal of oral poliovirus 
vaccines (OPVs) and replacement with inactivated poliovirus vaccines (IPVs). The first phase of this effort was the 
withdrawal of the serotype 2 vaccine in April 2016, with a switch from trivalent OPVs to bivalent OPVs. The aim of our 
study was to produce comparative estimates of humoral and intestinal mucosal immunity associated with different 
routine immunisation schedules.
Methods We did a random-effect meta-analysis with single proportions and a network meta-analysis in a Bayesian 
framework to synthesise direct and indirect data. We searched MEDLINE and the Cochrane Library Central Register 
of Controlled Trials for randomised controlled trials published from Jan 1, 1980, to Nov 1, 2018, comparing poliovirus 
immunisation schedules in a primary series. Only trials done outside western Europe or North America and without 
variation in age schedules (ie, age at administration of the vaccine) between study groups were included in the 
analyses, because trials in high-income settings differ in vaccine immunogenicity and schedules from other settings 
and to ensure consistency within the network of trials. Data were extracted directly from the published reports. We 
assessed seroconversion against poliovirus serotypes 1, 2, and 3, and intestinal immunity against serotype 2, measured 
by absence of shedding poliovirus after a challenge OPV dose.
Findings We identified 437 unique studies; of them, 17 studies with a maximum of 8279 evaluable infants were 
eligible for assessment of humoral immunity, and eight studies with 4254 infants were eligible for intestinal 
immunity. There was low between-trial heterogeneity in the data (τ=0·05, 95% credible interval [CrI] 0·009–0·15). For 
serotype 2, the risk ratio (RR) of seroconversion after three doses of bivalent OPVs was 0·14 (95% CrI 0·11–0·17) 
compared with three doses of trivalent OPVs. The addition of one or two full doses of an IPV after a bivalent OPV 
schedule increased the RR to 0·85 (0·75–1·0) and 1·1 (0·98–1·4). However, the addition of an IPV to bivalent OPV 
schedules did not significantly increase intestinal immunity (0·33, 0·18–0·61), compared with trivalent OPVs alone. 
For serotypes 1 and 3, there was susbstantial inconsistency and between-trial heterogeneity between direct and 
indirect effects, so we only present pooled estmates on seroconversion, which were at least 80% for serotype 1 and at 
least 88% for serotype 3 for all vaccine schedules.
Interpretation For WHO’s polio eradication programme, the addition of one IPV dose for all birth cohorts should be 
prioritised to protect against paralysis caused by type 2 poliovirus; however, this inclusion will not prevent transmission 
or circulation in areas with faecal–oral transmission.
Funding UK Medical Research Council.
Copyright Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the 
CC BY 4.0 license.
Introduction
In 1988, the World Health Assembly passed a resolu­
tion that committed WHO to eradicating poliomyelitis 
globally. The eradication effort has been centred on mass 
vaccination campaigns and achieving high routine 
immunisation coverage with Sabin oral poliovirus vaccines 
(OPVs) and Salk inactivated poliovirus vaccines (IPVs).1,2 
More than 150 countries have relied on OPVs to eliminate 
poliovirus transmission and maintain a polio­free status; 
however, the cessation of all OPV use and replacement by 
IPVs is necessary because of the risk of vaccine­derived 
poliovirus and vaccine­associated paralytic poliomyelitis 
associated with the OPV.3 The first phase of this cessation 
was completed in April 2016, with the global withdrawal of 
the type 2 strain OPV and a switch from the trivalent OPV 
(tOPV) to a bivalent OPV (bOPV) formulation. Additionally, 
the Strategic Advisory Group of Experts on Immunisation 
(SAGE) recommended that at least one dose of IPV 
was introduced into all routine immunisation schedules 
to protect against poliomyelitis caused by serotype 2.4 
However, constraints on IPV supply resulted in 39 countries 
having to delay IPV introduction or interrupt its routine 
use, with some countries adopting the use of intradermal 
fractional­dose IPV (fIPV).5
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After termination of OPV use, the post­eradication 
schedule is planned to comprise a minimum of 
two IPV doses given after 14 weeks of age.6 There are 
several approaches to developing affordable IPV options, 
including restricting the number of IPV doses in routine 
immunisation to two, reducing the volume of each dose 
through intradermal administra tion, reducing the 
antigen content of each dose through use of adjuvants, 
and reducing the cost of production through developing 
IPVs from attenuated vaccines of the Sabin strains of 
poliovirus.7,8 These approaches have resulted in the 
development of alternative formulations to conventional 
intramuscular Salk IPV, including intradermal fIPV, 
adjuvanted IPV, monovalent type 2 IPV (mIPV2), and 
Sabin IPV (sIPV).
Accordingly, many clinical trials have evaluated the 
imm uno genicity of different vaccine schedules. It is 
essen tial to develop a comprehensive overview of imm­
unity induced by different routine immunisation sched­
ules against the three poliovirus serotypes. Standard 
meta­analysis approaches combine information from 
multiple studies to estimate the overall effectiveness 
of an intervention, but do not compare effectiveness 
between interventions that have not been explicitly 
trialled. By contrast, network meta­analysis uses the 
quantitative relatedness (ie, relative effects) of inter­ 
ventions to estimate both the direct and indirect effects.9,10 
Although network meta­analyses are used increasingly to 
compare drugs, they have not been widely adopted to 
compare vaccine schedules.11,12
In this Article, we aim to estimate the relative 
immunogenicity of the different OPV and IPV routine 
immunisation sched ules considered by WHO and 
member states in inducing humoral and intestinal 
immunity against poliovirus. This knowledge would be 
useful to inform global immunisation policy.
Methods
Search strategy and selection criteria
We did a systematic review and network meta­analysis of 
randomised controlled trials comparing the immuno­
genicity of primary immunisation schedules for polio­
virus vaccines in healthy infants and providing efficacy 
outcomes of the vaccination. Interventions of IPV­only, 
IPV­bOPV combination, and bOPV­only vaccine schedules 
were included, in com parison with each other or with a 
tOPV­only schedule. Interventions were included if the 
age of administration of the first vaccine dose (excluding a 
dose at birth) was between 4 and 8 weeks of age. A full 
study protocol outlining the population, intervention, 
comparison, and outcome criteria used is available in the 
appendix (p 3).
We searched MEDLINE and Cochrane Library Central 
Register of Controlled Trials (CENTRAL) for randomised 
controlled trials published from Jan 1, 1980, to Nov 1, 2018, 
using the search terms: (polio OR poliovirus) AND 
Research in context
Evidence before this study
The phased removal of the oral polio vaccine (OPV) is occurring 
alongside introduction of the inactivated poliovirus vaccine (IPV), 
eradication of wild poliomyelitis cases, and prevention of the 
emergence and circulation of vaccine-derived polioviruses. We 
searched MEDLINE and the Cochrane Library Central Register of 
Controlled Trials for randomised controlled trials published from 
Jan 1, 1980, to Nov 1, 2018, that compare poliovirus 
immunisation schedules in primary series to compile in a network 
meta-analysis. We used the search terms: (polio OR poliovirus) 
AND vaccine AND (primary series OR routine OR infants) 
AND (seropositive OR seroconversion OR antibody OR mucosal 
immunity OR intestinal immunity). Only trials done outside 
western Europe or North America and without variation in age 
schedules between study groups were included in the analyses. 
We assessed the risk of bais with the Cochrane Collaboration’s 
tool for assessing bias in randomised trials and found it to be 
low-to-moderate for individual studies. The effect of various 
vaccine schedules on humoral and mucosal immunity has been 
addressed by many reviews and phase 3 clinical trials in different 
settings globally, creating a vast pool of recommendations for 
appropriate vaccine schedules.
Added value of this study
Schedules of bivalent OPV plus IPV have the potential to 
provide humoral immunity against serotype 2 poliovirus, which 
protects against paralysis from circulating vaccine-derived 
poliovirus of serotype 2. However, such a schedule will not 
induce intestinal protection against serotype 2, enabling 
transmission of this virus in some populations. There is 
little difference between the immunogenicity achieved 
through affordable IPV options (Salk IPV, Sabin IPV, 
fractional IPV, adjuvanted IPV, and monovalent IPV).
Implications of all the available evidence
Schedules of bivalent OPV plus IPV are recommended for 
routine immunisation in low-income and middle-income 
settings. Any vaccination programme must ensure that every 
child receives at least one dose of IPV to protect against 
poliomyelitis, which will require strong routine immunisation 
systems and catch-up of missed children. The interruption of 
all transmission of serotype 2 needs to be expedited and 
surveillance systems to detect circulating virus quickly 
need to be strengthened. Evidence supports the 
recommendations given by Strategic Advisory Group of 
Experts for the introduction of IPVs and the adoption of 
dose-sparing options, such as fractional IPV in times of 
IPV supply shortage.
See Online for appendix
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vaccine AND (primary series OR routine OR infants) 
AND (seropositive OR seroconversion OR antibody OR 
mucosal immunity OR intestinal immunity). Trials 
were excluded if they were done in western Europe or 
North America, because of differences in vaccine 
immunogenicity and schedules used in these high­
income settings, or if there was variation in age schedules 
(ie, age at administration of the vaccine) between study 
groups, to ensure consistency within the network of trials 
we analysed. The most relevant or inclusive data (ie, 
fitting the search criteria and most standard procedures) 
for a given study, with no differentiation between vaccine 
manufacturer, were chosen. We follow the Preferred 
Reporting Items for Systematic Reviews and Meta­
Analyses (PRISMA) guidelines to report our network 
meta­analysis.
We curated the retrieved studies on the basis of 
two predefined outcomes. The first outcome was 
seroconversion against poliovirus serotypes 1, 2, and 3, 
measured 4 weeks after the most recent vaccine 
dose. Seroconversion was defined as a change in antibody 
titre from non­detectable (<1:8) to detectable (≥1:8) 
antibody titre, or four­fold or higher increase in antibody 
titre over the expected decline of maternally derived 
antibodies (assuming a maternal antibody half­life of 
28 days).13 The second outcome was development of 
intestinal immunity against serotype 2. Immunity was 
measured as the absence of shedding of type 2 poliovirus 
7 days after a challenge dose of OPV containing the Sabin 
type 2 strain.
The studies were reviewed and the data extracted 
independently by two of the investigators (GM and 
KMO’R). The number of individuals in each study group 
was recorded by serotype and time of sample collection. 
We also extracted data for study location, age at 
administration, route of administration, vaccine anti­
gen content, and challenge vaccine and timing (where 
applicable). We assessed the risk of bias in accordance 
with the Cochrane Collaboration’s tool14 for assessing risk 
of bias in randomised trials, for individual elements from 
five domains (selection, performance, attrition, reporting, 
and other bias) and the overall quality of evidence 
using the Grading of Recommendations Assessment, 
Development, and Evaluation framework.15
Data analysis
We did a random­effect meta­analysis of single propor­
tions, using an inverse variance pooling method and logit 
transformation, in the meta package in R (version 3.4.3). 
A random­effect network meta­analysis was developed 
for each outcome, with a binomial likelihood and log­link 
function and computed in a Bayesian framework using 
the GeMTC package in R (version 3.4.3). Markov chain 
Monte Carlo (MCMC) simulations estimated posterior 
distributions of rela tive treatment effects and SDs, 
with vague uniform priors. Four independent Markov 
chains were run with 10 000 burn­in iterations and 
Figure 1: Systematic review profile
799 record abstracts identified through database searching
437 record abstracts after removing duplicates
384 abstracts did not meet the inclusion criteria
437 record abstracts screened
35 full-text articles excluded
 3 duplicate dataset
 16 full primary schedule not completed
 3 age schedule not consistent between study groups
 1 first dose administered at >10 weeks of age
 12 historical vaccination schedules
53 retrieved for full-text assessment
18 studies eligible for outcomes 1 and 2
17 studies included in humoral immunity analysis
 8 studies included in intestinal immunity analysis
Figure 2: Networks of eligible comparisons for vaccination schedules inducing humoral immunity against 
poliovirus serotypes 1, 2, and 3
Each node represents a vaccine schedule and the lines are direct comparisons. The width of the lines is proportional 
to the number of trials compared and the node size is proportional to the number of trials that include that 
schedule. Blue schedules include a birth dose and orange schedules do not. bOPV=bivalent oral poliovirus vaccine. 
fIPV=fractional inactivated poliovirus vaccine. IPV=conventional inactivated poliovirus vaccine. IPV-Al=aluminium 
hydroxide adjuvanted inactivated poliovirus vaccine. mIPV2=monovalent serotype 2 high-dose inactivated 
poliovirus vaccine. sIPV=Sabin inactivated poliovirus vaccine. tOPV=trivalent oral poliovirus vaccine.
1 IPV + 2 bOPV
2 fIPV
2 IPV
2 IPV + 1 bOPV
3 bOPV
3 bOPV
 + 1 IPV
3 bOPV
 + 1 mIPV2
3 bOPV + 2 IPV
3 fIPV
3 IPV
3 IPV−Al
3 sIPV
3 tOPV
4 bOPV
4 bOPV
 + 1 IPV
4 bOPV
 + 2 IPV
4 IPV
4 tOPV
fIPV + bOPV + fIPV
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60 000 inference iterations per chain. Convergence of 
Markov chains was evaluated using the Gelman–Rubin–
Brooke diagnostic and time­series plots.16 Autocorrelation 
plots were assessed to detect auto correlation in the 
chains. Additional analysis included network meta­
regression to investigate the effect of study­level 
covariates, including the estimated mortality rate for 
children younger than 5 years due to diarrhoeal disease 
in the country of study location.17
We report the pooled random­effect estimates for single­
proportion meta­analyses by study arm with 95% CIs. For 
the network meta­analysis, the between­intervention 
relative effects were summarised as risk ratios (RR) and 
reported as the median of the posterior distribution 
with 95% credible intervals (CrIs). Differ ences between 
treatments are considered significant (at the 5% level) if 
CIs do not overlap the no­effect line. The RRs are 
presented relative to a tOPV comparator and as relative­
effect tables between treatments (appendix p 21). Pairwise 
analysis is additionally reported for programmatically 
important comparisons (appendix p 27).
Model­fit was measured by deviance information 
criterion, residual deviance, and leverage.18 We show the 
SD of the random­effects model (known as τ), as a 
meas ure of heterogeneity in the network, where τ² 
is the between­study variance of the true effect size. A 
node­splitting model was generated to assess inconsistency 
within the network.10
Role of the funding source
The funders had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
The corresponding author had full access to all the data 
in the study and had final responsibility for the decision 
to submit for publication.
Results
A literature search in MEDLINE and CENTRAL identified 
437 unique studies and 53 were retrieved for full­text 
assessment (figure 1). 17 studies describing 47  study 
groups met the inclusion criteria and were included in the 
network meta­analysis for humoral immunity, and eight 
studies describing 25 study groups did so for intestinal 
immunity (appendix p 6–14). We found a low­to­moderate 
risk of bias for individual studies and a moderate­to­high 
quality of evidence for each outcome (appendix p 14). 
Seven vaccine formulations were included in the total 
analysis: tOPV, bOPV, Salk IPV (referred to as IPV and 
administered intramuscularly), mIPV2 (administered 
intramuscularly), fIPV (one­fifth Salk IPV dose, admin­
istered intradermally), sIPV (ad ministered intramuscu­
larly), and aluminium­adjuvanted IPV (IPV­Al; one­tenth 
Salk IPV dose, administered intramuscularly).
There were 19 unique vaccination schedules identified, 
and each formed a node in the network (figure 2) with 
corresponding schedules by patient age (table). The 
network was separated into two subgroups, studies 
without a birth dose (14 nodes, 15 studies) and those with 
a birth dose (five nodes, two studies). In total, 8254 infants 
were included in the analysis for seroconversion against 
serotype 1, 8241 against serotype 2, and 8279 against 
serotype 3. The pooled proportion for all three serotypes 
of individuals who underwent seroconversion ranged 
from 13% to 100% between diff erent vaccine schedules.
In the network meta­analysis, the criteria for adequate 
model­fit were satisfied with no significant inconsistency 
between any direct and indirect estimates (p<0·05 for 
all comparisons) and low between­trial heterogeneity 
(τ=0·05, 95% CrI 0·009–0·15; appendix p 18).
All vaccine schedules achieved higher seroconversion 
RRs against serotype 2 than bOPV alone (figure 3). The 
addition of a single dose of IPV to a three­dose bOPV 
schedule significantly improved seroconversion (at age 
18 weeks; RR 0·85, 95% CrI 0·75–1·0), and a second 
incremental increase in RR was seen after a second dose 
of IPV (at 36 weeks; 1·1, 0·98–1·4). A pairwise analysis of 
studies that directly compared seroconversion from 
three bOPV doses plus two IPV doses with three bOPV 
doses plus one IPV doses gave a pooled RR of 
1·25 (95% CrI 1·07–1·47; appendix p 27).
Combined bOPV­IPV schedules where IPV admin­
istration preceded bOPV had a lower RR than in cases in 
which IPV succeeded bOPV (figure 3).
Age schedule (weeks)
IPV + 2 bOPV 8, 12, 16 or 8, 16, 24
2 fIPV* 6, 14
2 IPV 6, 14
2 IPV + bOPV 8, 12, 16 or 8, 16, 24
3 bOPV 6, 10, 14
3 bOPV + IPV 6, 10, 14, 14
3 bOPV + mIPV2† 6, 10, 14, 14
3 bOPV + 2 IPV 6, 10, 14, 14, 36
3 fIPV* 6, 10, 14 or 8, 16, 24
3 IPV 6, 10, 14; 8, 12, 16; or 8, 16, 24
3 IPV-Al‡ 6, 10, 14
3 sIPV§ 8, 12, 16
3 tOPV 6, 10, 14 or 8, 12, 16
4 bOPV Birth, 6, 10, 14
4 bOPV + IPV Birth, 6, 10, 14, 14
4 bOPV + 2 IPV Birth, 6, 10, 14, 18
4 IPV Birth, 6, 10, 14
4 tOPV Birth, 4, 8, 12 or birth, 6, 10, 14
fIPV* + bOPV + fIPV* 6, 10, 14
bOPV=bivalent oral poliovirus vaccine. fIPV=fractional inactivated poliovirus vaccine. 
IPV=conventional inactivated poliovirus vaccine. IPV-Al=aluminium hydroxide 
adjuvanted inactivated poliovirus vaccine. mIPV2=monovalent serotype 2 high-dose 
inactivated poliovirus vaccine. sIPV=Sabin inactivated poliovirus vaccine. 
tOPV=trivalent oral poliovirus vaccine. *One-fifth full IPV dose administered 
intradermally. †32 D-antigen content for serotype 2 administered intramuscularly. 
‡One-tenth full IPV dose administered intramuscularly. §30, 32, and 45 D-antigen 
content for serotype 1, 2, and 3, respectively, administered intramuscularly.
Table: Vaccine schedules by approximate age of administration included 
for each node of the network meta-analysis for humoral immunity
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We compared IPV­only schedules for both two and three 
doses (see appendix p 21 for a table of relative effects). 
There was no significant difference between the 
seroconversion achieved by two doses of full­dose IPV and 
intradermal fIPV (RR 0·88, 95% CrI 0·74–1·02). Adding a 
third dose to the schedule gave no significant increase in 
seroconversion: the RR was 0·96 (0·81–1·15) for two 
versus three doses of full­dose IPV, and 1·01 (0·85–1·20) 
for two versus three doses of intradermal fIPV. Addi­
tionally, there was no significant difference between three 
doses of any alternative IPV formulation with Salk IPV, 
fIPV (0·92, 0·83–1·0), sIPV (1·01, 0·93–1·10), or IPV­Al 
(0·96, 0·83–1·11).
For schedules including a birth dose from the full 
network analysis, the addition of one or two doses of IPV 
following a four­dose bOPV­only schedule increased sero­
conversion (figure 3).
For the network meta­analysis of serotype 1, there was 
significant inconsistency between direct and indirect 
effects in one network comparison, and in six comparisons 
for serotype 3. There was high between­trial heterogeneity 
for both serotypes (serotype 1 τ=0·24, 95% CrI 
0·12–0·48; serotype 3 τ=0·17, 0·09–0·32; appendix p 20). 
Therefore, we present the results of the individual trial 
data and pooled estimates only: all vaccine schedules had 
pooled estimates for seroconversion of at least 80% for 
serotype 1 and at least 88% for serotype 3 (figure 4). For 
both serotypes, three doses of bOPV alone gave high 
seroconversion (figure 4). Additionally, there was little 
difference in seroconversion between three doses of IPV, 
fIPV, sIPV or IPV­Al, or between two doses of IPV and 
fIPV (figure 4).
There were 15 unique vaccination schedules identified 
for intestinal immunity against serotype 2 (see appendix p 
29 for the single­proportion meta­analysis). The average 
Figure 3: Relative immunogenicity of vaccine schedules for seroconversion 
against poliovirus serotype 2 schedules with no birth dose and schedules 
with a birth dose
Between-trial heterogeneity for (A) schedules without a birth dose (τ=0·05, 
95% CrI 0·009–0·15) and (B) those with a birth dose (0·23, 0·026–1·31). 
bOPV=bivalent oral poliovirus vaccine. CrI=credible interval. fIPV=fractional 
inactivated poliovirus vaccine administered intradermally (one-fifth dose of IPV). 
IPV=conventional inactivated poliovirus vaccine. IPV-Al=aluminium hydroxide 
adjuvanted inactivated poliovirus vaccine (one-tenth reduced dose of IPV). 
mIPV2=monovalent serotype 2 high-dose inactivated poliovirus vaccine. 
sIPV=Sabin inactivated poliovirus vaccine. tOPV=trivalent oral poliovirus vaccine.
Risk ratio (95% Crl)
Compared with 3 tOPV
3 IPV
3 fIPV
3 IPVAl
3 sIPV
2 IPV
2 fIPV
3 bOPV
3 bOPV + 1 IPV
3 bOPV + 1 mIPV2
3 bOPV + 2 IPV
1 IPV + 2 bOPV
2 IPV + 1 bOPV
fIPV + bOPV + fIPV
 0·88 (0·78–0·98)
 0·81 (0·69–0·92)
 0·85 (0·69–1·00)
 0·89 (0·76–1·00)
 0·92 (0·78–1·00)
 0·80 (0·69–0·91)
 0·14 (0·11–0·17)
 0·85 (0·75–1·00)
 1·10 (0·86–1·40)
 1·10 (0·98–1·40)
 0·62 (0·50–0·71)
 0·80 (0·68–0·91)
 0·82 (0·70–0·94)
A
Risk ratio (95% Crl)
Compared with 4 tOPV
4 bOPV
4 bOPV + 1 IPV
4 bOPV + 2 IPV
4 IPV
 0·21 (0·13–0·32)
 0·63 (0·42–0·93)
 0·99 (0·59–1·70)
 0·94 (0·56–1·60)
10·1 8
Favours 4 tOPV Favours another
schedule
10·1 8
Favours another
schedule
Favours 3 tOPV
B
Figure 4: Random-effect single-proportion meta-analysis estimate of the proportion of children undergoing 
seroconversion against serotypes 1 (A) and 3 (B)
Overall REM estimates and heterogeneity were 0·97 (95% CrI 0·96–0·98) and τ²=1·66 for serotype 1 and 
0·97 (0·96–0·98) and τ-squared=1·38 for serotype 3. Individual studies are shown as dots, with the overall 
estimated proportion as a vertical line through each dot and 95% CrI as shading. bOPV=bivalent oral poliovirus 
vaccine. CrI=credible interval. fIPV=fractional inactivated poliovirus vaccine administered intradermally 
(one-fifth dose of IPV). IPV=conventional inactivated poliovirus vaccine. IPV-Al=Aluminium hydroxide adjuvanted 
inactivated poliovirus vaccine (one-tenth reduced dose of IPV). mIPV2=monovalent serotype 2 high-dose 
inactivated poliovirus vaccine. REM=random effect model. sIPV=Sabin inactivated poliovirus vaccine. 
tOPV=trivalent oral poliovirus vaccine
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proportion of individuals who developed intestinal 
immunity was 0·91 (95% CI 0·70–0·98) following 
three tOPV doses, 0·30 (0·17–0·48) following three bOPV 
doses, 0·25 (0·22–0·29) following three bOPV doses plus 
one IPV dose, and 0·28 (0·22–0·29) following three bOPV 
doses plus two IPV doses. Heterogeneity was high 
between studies, and was significant for schedules of 
three tOPV doses (τ=1·56, p<0·01), three bOPV doses 
(τ=0·53, p<0·01), and four bOPV doses plus one IPV dose 
(τ=0·77, p<0·01).
Only four routine immunisation schedules had data 
from multiple studies: three tOPV, three bOPV, 
three bOPV plus one IPV, and three bOPV plus two IPV 
doses. Therefore, another network was generated out of 
these four nodes, which was directed at a programmatic 
question of the added benefit of IPV to intestinal 
immunity (figure 5). Intestinal immunity was 
significantly lower for all sched ules than three doses of 
tOPV. The addition of one or two doses of IPV to 
three doses of bOPV did not substantially alter the risk 
(figure 5).
Discussion
To our knowledge, we report the first application of a 
network meta­analysis to assess the immunogenicity of 
vaccine schedules against poliomyelitis and provide a 
single, comprehensive analysis of polio routine immun­
isa tion schedules for humoral and intestinal outcomes. 
We found that for humoral immunity the addition of one 
dose of IPV to bOPV schedules increases the immunity 
against serotype type 2, that there is no difference in 
relative immuno genicity of IPV variants (Salk IPV, sIPV, 
intradermal fIPV, IPV­Al), and that the timing of the 
IPV dose in bOPV­IPV schedules is associated with 
immunogenicity. Potentially, the most important finding 
of our study is for mucosal immunity, as we found no 
evidence of increased intestinal immunity against 
serotype 2 associated with an addition of IPV to a bOPV­
only schedule.
Clinical trials have provided valuable information to 
inform policy but are limited by specific head­to­head 
schedule comparisons, small cohort sizes, and genera­
tion of country­specific data. Previous literature reviews 
and meta­analyses have addressed specific aspects of 
vaccination against poliomyelitis virus: mucosal immunity 
induced by OPV versus IPV,19 humoral immunity of 
one versus two doses of IPV,20 and immunogenicity 
of two doses of fIPV.21 Additionaly, reviews and meta­
analysis have compared the immunogenicity of bOPV­
IPV mixed schedules and IPV alone.22,23 In agreement with 
our results, a meta­analysis by Tang and colleagues23 
found no significant difference between IPV­only and 
IPV­OPV schedules in seroconversion against serotypes 1 
and 3. However, they included only six trials with 
two different schedule groups (IPV­only and IPV­OPV 
mixed sched ule) and provided no data on mucosal 
immunity. There fore, our analysis goes beyond what 
previous studies have done.
After the switch from tOPV to bOPV, SAGE recom­
mended the introduction of at least one dose of IPV at 
age 14 weeks or older to provide an immunity base to 
type 2 poliovirus. Our results provided evidence that 
individuals vaccinated with bOPV­only schedules have 
negligible immunity against poliovirus 2 (probably from 
passive type­2 exposure or antibody cross­neutralisation 
from types 1 and 3). This immunity deficit suggests that 
the estimated 43 million children across 33 countries 
who did not recieve IPV because of supply shortages 
have no protection.24 Notably, the addition of a single 
dose of IPV (at 14 weeks) improved humoral immunity 
against serotype 2, whereas a second dose (at 18 or 
36 weeks) had a smaller impact and a single mIPV2 dose 
provided equivalent immuno genicity to two doses of 
trivalent IPV. Our results also highlight that the order 
and timing of the IPV dose in mixed schedules is 
important, with a reduced immuno genicity against the 
type 2 strain in cases where IPV preceded bOPV. This 
effect is likely due to the earlier age at which IPV is 
administered and the effect of maternal antibodies.25
Figure 5: Network meta-analysis of routine immunisation schedules for 
intestinal immunity against serotype 2
(A) Network plot. Each node represents a vaccine schedule and the lines are 
direct comparisons. The width of the lines is proportional to the number of trials 
compared and the node size is proportional to the number of trials that include 
that schedule. (B) Relative risk of absence of shedding vaccine-derived poliovirus 
after challenge, compared with three tOPV doses. Data are risk ratio (95% CrI). 
bOPV=bivalent oral poliovirus vaccine. CrI=credible interval. IPV=conventional 
inactivated poliovirus vaccine. tOPV=trivalent oral poliovirus vaccine.
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Of note, the addition of IPV had a negligible effect on the 
development of intestinal immunity against sero type 2. 
Although the ability of IPV to induce humoral immunity is 
established, IPV has a more complex role in mucosal 
imm un ity. IPV­only schedules provide inade quate intesti­
nal immunity and do not prevent viral shedding following 
a challenge dose, but they might reduce the quantity and 
duration of shedding.26,27 How ever, IPV has been shown to 
boost mucosal protection in OPV­primed individuals.26 
Our results provide evidence that the prime­boost model 
established for IPV works in a serotype­specific manner.
Our findings have several limitations. Consistency of 
the network is a fundamental assumption of network 
meta­analyses,9,10 which was not met for serotypes 1 and 3 
for which heterogeneity and inconsistency persisted 
through the subgroup and regression analyses (appendix 
p 18–20). The type, schedule, and immunogenicity of 
poliovirus vaccines varies by location.3 The studies in this 
analysis3 were done in eastern Mediterranean and Latin 
American countries that have primary vaccine schedules 
in which the first (non­birth) dose is administered 
between 4 and 8 weeks. Therefore, our results are 
primarily useful for policy makers in these settings. The 
geographical and age­schedule variation in absolute 
immunogenicity is incorporated into our study as the 
network meta­analysis method models the relative effects 
be tween vaccines, thus eliminating differences in 
baseline immunogenicity of comparator schedules.28
The most widely adopted measure of poliovirus 
mucosal immunity is through administration of a 
challenge dose of OPV and a subsequent collection of 
stool samples. Extrapolating intestinal immunity and 
transmission impact on the basis of absence of shedding 
7 days following a challenge dose does not capture the 
duration of shedding, quanitity of virus shed, or 
nasopharengeal immunity.19,26 However, these meaures 
represent the best proxy for intestinal immunity to 
poliovirus available from clinical trial data. Finally, our 
analysis only provides estimates on protection within the 
timescale of the trials.
There are research gaps highlighted in our modelled 
networks, particularly the need for evaluation of mucosal 
immunity in more studies. A schedule of three bOPV 
doses followed by fIPV has not been included in 
randomised controlled trials, yet this schedule has been 
adopted in India and Sri Lanka.6 Research is needed to 
compare IPV­only vaccine schedules in a post­eradication 
setting and address the need to develop a live vaccine with 
improved genetic stability. A novel OPV, which is a live 
attenuated vaccine with a lower risk of reversion than the 
standard OPV, and an IPV plus dmLT adjuvant are being 
trialled for induction of mucosal immun ity.6,29–31
The findings of our comprehensive analysis show that a 
network meta­analysis is effective to evaluate multi­arm 
vaccination studies. Our results support, with policy 
recommendations from the SAGE, the addition of IPV 
into routine immunisation schedules and the adoption of 
affordable IPV approaches. We show that a single dose of 
IPV improves humoral immunity against serotype 2 and 
suggest that in times of IPV supply constraints, equitable 
distribution of a single dose of IPV should be prioritised 
over cohorts receiving a second dose, taking into account 
country­specific risk. This IPV addition will be unlikely to 
prevent faecal–oral transmission of the virus, but would 
provide individual protection against paralytic disease.
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